SCHEMBL824764

SCHEMBL824764

CCCC(F)(F)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL30110441 0.97
SCHEMBL8367425 0.85
SCHEMBL28157868 0.84
SCHEMBL19299987 0.81
SCHEMBL8366370 0.80
SCHEMBL16925357 0.78 CES2 (0.43)
SCHEMBL9232312 0.76
SCHEMBL82375 0.76
SCHEMBL30697411 0.76 CES2 (0.36)
SCHEMBL1470474 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115458808-B Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery 三菱化学株式会社 2026-05-15 CN disclosed
WO-2024050370-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. (US) 2024-03-07 WO disclosed
EP-4234545-A2 HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2023-08-30 EP disclosed
EP-4186528-A1 OLIGOSACCHARIDE COMPLEXES AND USES BioNTech SE (DE) 2023-05-31 EP disclosed
WO-2023088231-A1 NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND PREPARATION METHOD THEREFOR 北京泰德制药股份有限公司 2023-05-25 WO disclosed
WO-2023067125-A1 OLIGOSACCHARIDE COMPLEXES AND USES BioNTech SE (DE) 2023-04-27 WO disclosed
WO-2022171128-A1 PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE SERVING AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2022-08-18 WO disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 WO disclosed
WO-2022058920-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 WO disclosed
WO-2022015957-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-01-20 WO disclosed
US-7842626-B2 Partially fluorinated compositions and surface active agents E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-11-30 US disclosed
US-20090269305-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-10-29 US disclosed
US-20090076033-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination ROBL JEFFREY A 2009-03-19 US disclosed
US-7473658-B2 Partially fluorinated amino acid derivatives as gelling and surface active agents E. I. DU PONT NEMOURS AND COMPANY (US) 2009-01-06 US disclosed
US-20080113172-A1 Partially fluorinated compositions and surface active agents E. I. DU PONT DE NEMOURS AND COMPANY 2008-05-15 US disclosed
US-20080113573-A1 Partially fluorinated amino acid derivatives as gelling and surface active agents E. I. DU PONT DE NEMOURS AND COMPANY 2008-05-15 US disclosed
US-7358254-B2 Method for treating atherosclerosis employing an aP2 inhibitor and combination BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-15 US disclosed
US-5254755-A Solvents, cleaning compounds ALLIED-SIGNAL INC. (US) 1993-10-19 US disclosed
WO-1992010454-A1 PARTIALLY FLUORINATED ALKANOLS HAVING A TERTIARY STRUCTURE ALLIED-SIGNAL INC. (US) 1992-06-25 WO disclosed
US-3976691-A Dialkylaminosulfur trifluorides as fluorinating agents E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-08-24 US disclosed